Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

The use of IORT at Montefiore Medical Center

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM